"The archconservative U.S. Court of Appeals for the 5th Circuit issued a stunning nationwide injunction that directly affects one-fourth of all abortions in the United States. The opinion rejected an FDA regulation allowing people to buy mifepristone, a drug used for medication abortion and miscarriage management, by mail."
"The 5th Circuit's ruling undoes the FDA's rule that allowed access to mifepristone via telehealth, a change that was made permanent in 2023 after extensive review of safety data."
"This time, the Trump administration is complicit in the circuit court's ruling, while trying to stay under the radar, contrasting with the previous administration's efforts to maintain access to mifepristone."
The 5th Circuit issued a nationwide injunction against the FDA regulation allowing mifepristone to be mailed, affecting one-fourth of U.S. abortions. This ruling applies even in states without abortion bans. The Supreme Court temporarily halted the ruling, allowing mifepristone to be mailed for now. The FDA had previously approved mifepristone in 2000 and relaxed restrictions over time, including allowing telehealth prescriptions. The recent ruling threatens these changes, particularly the ability to mail abortion pills via telehealth, which was made permanent in 2023.
Read at Slate Magazine
Unable to calculate read time
Collection
[
|
...
]